Stone Alan
Medical Scientific Advisory Services Ltd, London, UK.
Reprod Health Matters. 2014 Nov;22(44):213-7. doi: 10.1016/S0968-8080(14)44801-8.
Global statistics on unplanned pregnancies, abortions and STIs show that unprotected sex is still widely practised. More needs to be done to provide women and men with a wider choice of convenient protective options. To address this need, international efforts are focusing on developing multipurpose prevention technologies (MPTs) that address two or more indications simultaneously. These technologies would have significant advantages over single-indication products. They include inter alia novel barrier devices, drugs administered either as oral tablets or vaginal/rectal gels, drugs used in combination with medical devices, and genetically engineered organisms which secrete antimicrobial substances. As an example of progress in the MPT field, this paper describes an on-demand contraceptive/antimicrobial vaginal gel, Amphora (previously known as Acidform), now in an advanced stage of development. Clinical trials are currently being planned to find out whether this product's promising antimicrobial profile translates into protective and preventive choices.
全球意外怀孕、堕胎和性传播感染的统计数据表明，无保护性行为仍然广泛存在。需要做出更多努力，为男性和女性提供更多便捷的保护选择。为满足这一需求，国际社会正致力于开发同时解决两种或更多适应症的多功能预防技术（MPT）。这些技术相对于单一适应症产品具有显著优势。它们尤其包括新型屏障装置、口服片剂或阴道/直肠凝胶形式的药物、与医疗器械联合使用的药物，以及分泌抗菌物质的基因工程生物。作为MPT领域进展的一个例子，本文介绍了一种按需使用的避孕/抗菌阴道凝胶——安芙兰（以前称为酸型凝胶），目前正处于开发的后期阶段。目前正在计划进行临床试验，以确定该产品有前景的抗菌特性是否能转化为保护和预防选择。
